Filters








3,537 Hits in 4.5 sec

Generative FDG-PET and MRI Model of Aging and Disease Progression in Alzheimer's Disease

Juergen Dukart, Ferath Kherif, Karsten Mueller, Stanislaw Adaszewski, Matthias L. Schroeter, Richard S. J. Frackowiak, Bogdan Draganski, Olaf Sporns
2013 PLoS Computational Biology  
Here, we provide and validate at a group level a generative anatomical model of glucose hypo-metabolism and atrophy progression in AD based on FDG-PET and sMRI data of 80 patients and 79 healthy controls  ...  The model suggests greater and more consistent changes in FDG-PET compared to sMRI at earlier and the inversion of this pattern at more advanced AD stages.  ...  Data used in preparation of this article were obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI) database (adni.loni.ucla.edu).  ... 
doi:10.1371/journal.pcbi.1002987 pmid:23592957 pmcid:PMC3616972 fatcat:sulattubbzc2vmoxmds2ke7qam

Different definitions of neurodegeneration produce similar amyloid/neurodegeneration biomarker group findings

Clifford R. Jack, Heather J. Wiste, Stephen D. Weigand, David S. Knopman, Michelle M. Mielke, Prashanthi Vemuri, Val Lowe, Matthew L. Senjem, Jeffrey L. Gunter, Denise Reyes, Mary M. Machulda, Rosebud Roberts (+1 others)
2015 Brain  
We assessed demographic associations with N + , and A/N biomarker group frequencies by age where A + was defined by amyloid PET and N + was defined in five different ways: (i) abnormal adjusted hippocampal  ...  70s and declined thereafter; and3 (iii) the frequency of AÀN + (suspected non-Alzheimer's pathophysiology) and of A + N + increased monotonically beginning in the mid-50s and mid-60s, respectively.  ...  Both FDG PET and MRI are widely used measures of neurodegeneration (Jagust et al., 2009) where neurodegeneration is defined as progressive loss of neurons and their processes with a corresponding progressive  ... 
doi:10.1093/brain/awv283 pmid:26428666 pmcid:PMC4655341 fatcat:rezcndntszhqze2yf5ncsqcb4q

Prognostic value of Alzheimer's biomarkers in mild cognitive impairment: the effect of age at onset

Daniele Altomare, for the Alzheimer's Disease Neuroimaging Initiative, Clarissa Ferrari, Anna Caroli, Samantha Galluzzi, Annapaola Prestia, Wiesje M. van der Flier, Rik Ossenkoppele, Bart Van Berckel, Frederik Barkhof, Charlotte E. Teunissen, Anders Wall (+9 others)
2019 Journal of Neurology  
Finally, FDG-PET showed a different prognostic value between earlier and later onset patients (p = 0.040) in time-to-progression allowing an estimate of the time free from disease.  ...  The aim of this study is to assess the impact of age at onset on the prognostic value of Alzheimer's biomarkers in a large sample of patients with mild cognitive impairment (MCI).  ...  Previous studies compared biomarker diagnostic value in EO and LO patients with Alzheimer's disease, finding highest diagnostic value for MRI in LO [16] , and for FDG-PET in EO patients with Alzheimer's  ... 
doi:10.1007/s00415-019-09441-7 pmid:31267207 fatcat:eqdykva2r5bvng5bhrdx76rao4

Relative contributions of biomarkers in Alzheimer's disease

Thaddeus J. Haight, William J. Jagust
2012 Annals of Epidemiology  
, and were used to examine, at any given time, the joint contributions of hippocampal volume, whole brain volume, and brain glucose metabolism on clinical AD progression, using the Alzheimer's Disease  ...  Effects of brain glucose metabolism differed in subgroups defined by baseline covariates (e.g., age), but no subgroup effects were observed for hippocampal volume and brain volume.  ...  Acknowledgments Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904).  ... 
doi:10.1016/j.annepidem.2012.09.004 pmid:23102709 pmcid:PMC3510749 fatcat:jf5wusd7p5fsnbefqlewhcu64a

Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers

Clifford R Jack, David S Knopman, William J Jagust, Ronald C Petersen, Michael W Weiner, Paul S Aisen, Leslie M Shaw, Prashanthi Vemuri, Heather J Wiste, Stephen D Weigand, Timothy G Lesnick, Vernon S Pankratz (+2 others)
2013 Lancet Neurology  
In 2010, we put forward a hypothetical model of the major biomarkers of Alzheimer's disease (AD).  ...  The model was received with interest because we described the temporal evolution of AD biomarkers in relation to each other and to the onset and progression of clinical symptoms.  ...  Acknowledgments We have received funding from the National Institutes of Health, grant AG11378.  ... 
doi:10.1016/s1474-4422(12)70291-0 pmid:23332364 pmcid:PMC3622225 fatcat:dfrw7udp65ayjmq65joch4sica

Grant Report on PREDICT-ADFTD: Multimodal Imaging Prediction of AD/FTD and Differential Diagnosis

2019 Journal of Psychiatry and Brain Science  
Studies utilizing FDG-PET have shown significant predictive ability in the prediction and progression of disease.  ...  Further, we evaluated multimodal models that combine structural and FDG-PET imaging, in order to compare the predictive power of multimodal to unimodal models.  ...  ACKNOWLEDGMENTS ADNI data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department  ... 
doi:10.20900/jpbs.20190017 pmid:31754634 pmcid:PMC6868780 fatcat:f65tcg424rcv7cbymqwa7pvkdi

A new data analysis approach for measuring longitudinal changes of metabolism in cognitively normal elderly adults

Sepideh Shokouhi, William Riddle, Hakmook Kang
2017 Clinical Interventions in Aging  
Previously, we discussed several critical barriers in including [ 18 F] fluorodeoxyglucose positron emission tomography ([ 18 F]FDG-PET) imaging of preclinical Alzheimer's disease (AD) subjects.  ...  In this study, we utilized a novel FDG-PET analysis, the regional FDG time correlation coefficient, rFTC, that can address and resolve these barriers and provide a more sensitive way of monitoring longitudinal  ...  Age and gender were included as fixed effects in all models.  ... 
doi:10.2147/cia.s150859 pmid:29276381 pmcid:PMC5734228 fatcat:sgizuabhlnh3xiqynpcqeylxqu

Longitudinal Change of Biomarkers in Cognitive Decline

Raymond Y. Lo
2011 Archives of Neurology  
imaging and their relative associations with cognitive change at different stages in aging and Alzheimer disease (AD).  ...  Setting: The 59 study sites for the Alzheimer's Disease Neuroimaging Initiative.  ...  ␤42 level in the CSF, FDG-PET regional metabolism, and MRI hippocampal volume.  ... 
doi:10.1001/archneurol.2011.123 pmid:21670386 pmcid:PMC5604752 fatcat:x4tqesjn3zcktoafme3wvw2x2e

Comparison of Regional Gray Matter Atrophy, White Matter Alteration, and Glucose Metabolism as a Predictor of the Conversion to Alzheimer's Disease in Mild Cognitive Impairment

Bo Kyung Sohn, Dahyun Yi, Eun Hyun Seo, Young Min Choe, Jee Wook Kim, Shin Gyeom Kim, Hyo Jung Choi, Min Soo Byun, Jin Hyeong Jhoo, Jong Inn Woo, Dong Young Lee
2015 Journal of Korean medical science  
We compared the predictive ability of the various neuroimaging tools and determined the most cost-effective, non-invasive Alzheimer's disease (AD) prediction model in mild cognitive impairment (MCI) individuals  ...  Thirty-two MCI subjects were evaluated at baseline with [ 18 F]-fluorodeoxyglucose positron emission tomography (FDG-PET), MRI, diffusion tensor imaging (DTI), and neuropsychological tests, and then followed  ...  DISCLOSURE The authors have no conflicts of interest to disclose. AUTHOR CONTRIBUTION  ... 
doi:10.3346/jkms.2015.30.6.779 pmid:26028932 pmcid:PMC4444480 fatcat:i2hi4phpjndghp7opt6q3movfm

Glucose metabolism reflects local atrophy and tau pathology in symptomatic Alzheimers disease [article]

Amelia Strom, Leonardo Iaccarino, Lauren Edwards, Orit H. Lesman-Segev, David N. Soleimani-Meigooni, Julie Pham, Suzanne L. Baker, Susan Landau, William J. Jagust, Bruce L. Miller, Howard J. Rosen, Maria Luisa Gorno-Tempini (+2 others)
2021 medRxiv   pre-print
age and disease severity (local model).  ...  ) underwent MRI and PET with FDG, amyloid-PET using [11C]-Pittsburgh Compound B, [18F]-Florbetapir, or [18F]-Florbetaben, and [18F]-Flortaucipir tau-PET within one year.  ...  Amyloid-and FTP-PET are presented in SUVR units and FDG-PET and MRI volume in age-adjusted z-score, or W-score, units compared to cognitively normal controls.  ... 
doi:10.1101/2021.03.08.21252999 fatcat:jqj7a5abnjbnhifk2tt4ilwsca

Biomarker Modeling of Alzheimer's Disease

Clifford R. Jack, David M. Holtzman
2013 Neuron  
Alzheimer's disease (AD) is a slowly progressing disorder in which pathophysiological abnormalities, detectable in vivo by biomarkers, precede overt clinical symptoms by many years to decades.  ...  In this Review, we discuss several time-dependent models of AD that take into consideration varying age of onset (early versus late) and the influence of aging and co-occurring brain pathologies that commonly  ...  Figure labels are as in (A), except here the CSF tau, structural MRI, and FDG PET are grouped under the generic neurodegenerative label.  ... 
doi:10.1016/j.neuron.2013.12.003 pmid:24360540 pmcid:PMC3928967 fatcat:6la475cxe5fnvc5vc2x72nb73m

The Alzheimer's Disease Neuroimaging Initiative phase 2: Increasing the length, breadth, and depth of our understanding

Laurel A. Beckett, Michael C. Donohue, Cathy Wang, Paul Aisen, Danielle J. Harvey, Naomi Saito
2015 Alzheimer's & Dementia  
Amyloid imaging and magnetic resonance imaging (MRI) summaries were assessed as predictors of disease progression.  ...  INTRODUCTION-The Alzheimer's Disease Neuroimaging Initiative (ADNI) is a multi-site study designed to characterize the trajectories of biomarkers across the aging process.  ...  ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Alzheimer  ... 
doi:10.1016/j.jalz.2015.05.004 pmid:26194315 pmcid:PMC4510463 fatcat:d6u3dg3dqzasbeeeioud7jed3q

Quantitative multimodal multiparametric imaging in Alzheimer's disease

Qian Zhao, Xueqi Chen, Yun Zhou
2016 Brain Informatics  
Alzheimer's disease (AD) is a progressive neurodegenerative disorder, causing changes in memory, thinking, and other dysfunction of brain functions.  ...  Fluorodeoxyglucose (FDG) PET and amyloid PET are applied in clinics and research departments.  ...  in transgenic mouse models of Alzheimer's disease.  ... 
doi:10.1007/s40708-015-0028-9 pmid:27747597 pmcid:PMC4883163 fatcat:dj7x4hkj4vg4fp55ib3mscjtgu

Potential Clinical Value of Multiparametric PET in the Prediction of Alzheimer's Disease Progression

Xueqi Chen, Yun Zhou, Rongfu Wang, Haoyin Cao, Savina Reid, Rui Gao, Dong Han, Kewei Chen
2016 PLoS ONE  
of Alzheimer's disease (AD) progression.  ...  A logistic regression model to combine FDG parietal and posterior precuneus SUVR and Alzheimer's PLOS ONE | Disease Assessment Scale-Cognitive (ADAS-Cog) Total Mod was identified in predicating NC progression  ...  ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: Author Contributions Conceived  ... 
doi:10.1371/journal.pone.0154406 pmid:27183116 pmcid:PMC4868310 fatcat:lxhzwih475hpta4ntmvhfrxf5a

Multimodal Discrimination between Normal Aging, Mild Cognitive Impairment and Alzheimer's Disease and Prediction of Cognitive Decline

Corinna Bauer, Howard Cabral, Ronald Killiany
2018 Diagnostics  
a sample of normal aging subjects and those with MCI and AD from the Alzheimer's Disease Neuroimaging Initiative.  ...  To achieve these aims, a series of multivariate stepwise logistic and linear regression models were generated.  ...  Data collection and sharing for this project was funded by the Alzheimer's Disease Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense  ... 
doi:10.3390/diagnostics8010014 pmid:29415470 pmcid:PMC5871997 fatcat:xdh754wx7bb2lk4owed6tt3lha
« Previous Showing results 1 — 15 out of 3,537 results